NCT04865107View on ClinicalTrials.gov

Cellular Immuno-Therapy for COVID-19 ARDS Randomized Clinical Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 27, 2021

Primary Completion Date

April 1, 2022

Study Completion Date

April 1, 2022

Conditions
Covid19Acute Respiratory Distress Syndrome
Interventions
BIOLOGICAL

UC-MSCs

3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)

BIOLOGICAL

Placebo

PlasmaLyte A and 5% Human Albumin

Trial Locations (4)

ON L1G 2B9

Lakeridge Health, Oshawa

K1H 8L6

The Ottawa Hospital, Ottawa

M5B 1W8

St. Michael's Hospital, Toronto

H2X 3E4

Centre Hospitalier de l'Université de Montréal, Montreal

Sponsors
All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

Ottawa Hospital Research Institute

OTHER